Albany Molecular Research, Inc. Rebrands to AMRI, Unveils New Corporate Identity
Albany Molecular Research, Inc. (NASDAQ: AMRI), with multiple locations in the United States, Europe and Asia, announced today that it has changed its brand name to “AMRI”. As a result, Albany Molecular Research, Inc. is now conducting its business throughout the world as “AMRI”.
This rebranding, which includes a new corporate logo, reflects the company’s evolution over 16 years into a global contract services and R&D organization. AMRI now provides a continuum of scientific services, products and technologies to the life sciences industry. The new brand encompasses all of the company’s subsidiaries, including operations in the United States, Europe and Asia.
“This rebranding of Albany Molecular Research, Inc. to AMRI reflects the company’s evolution from a small regional operation to a much larger business on a global scale,” said AMRI Chairman, President and CEO Thomas E. D’Ambra, Ph.D. “The new brand allows us to connect to our past to retain and build on our commitment to customer satisfaction and loyalty; at the same time creating a modern and dynamic global identity as we continue our transition into a larger company. Additionally, it is an opportunity for us to reinforce a common mission and purpose across all of our locations and technologies, versus the multiple and sometimes confusing identities of several different site names.”
AMRI’s new logo replaces a transitional logo that, since 2006, has included both “Albany Molecular Research, Inc.” and “AMRI” in order to highlight the association between the two names and set the stage for the transfer of Albany Molecular Research, Inc.’s strong brand equity to the new name, AMRI. The new logo retains elements of the original design while symbolizing AMRI’s evolution into a global, modern business.
While the legal name of the company will not be affected by the rebranding, the name of Organichem Corporation—a wholly owned subsidiary of AMRI located in Rensselaer, New York—has been legally changed to AMRI Rensselaer, Inc., and will be included under the AMRI brand.
Communications with the new AMRI logo will begin to appear on company materials and correspondence immediately.
Founded in 1991, AMRI provides scientific services, products and technologies that improve quality of life while delivering excellence, value and maximum return. AMRI's core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing; and a separate, standalone R&D division comprising proprietary technologies, internal drug discovery and bundled capabilities designed for more collaborative relationships. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services and cost models.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as “may,” “could,” “should,” “would,” “will,” “intend,” “expect,” “anticipate,” “believe” and “continue” or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on March 15, 2007 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Source:
Press Release
